Pharma Reports
Market Scope uses a multi-source methodology when preparing our annual and quarterly reports. We incorporate surgeon surveys, our extensive database of physicians and surgery centers, disease models, clinical studies, financial reports, and more. Our wide-ranging knowledge of products and technology and our comprehensive network of industry contacts also contribute to our coverage on the ophthalmic industry.
2023 Retinal Pharmaceuticals Market Report: Global Analysis for 2022 to 2028, August, 2023
The “2023 Retinal Pharmaceuticals Market Report” analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market’s evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 29 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.
2023 US and Western Europe Cataract Pharmaceuticals Market Report, May, 2023
The “2023 US and Western Europe Cataract Pharmaceuticals Market Report” offers an in-depth examination of the current cataract pharmaceuticals market in the United States and Western Europe and forecasts market performance over the next five years. The report analyzes the current market and forecasts units, average sales price, and revenue through 2028 by product category. It analyzes products currently on the market and examines the development pipeline, discusses the popularity of intracameral injections and fixed combination eye drops, and analyzes the roles of brand name medications, generics, and compounded formulations.
2023 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2022 to 2028, February, 2023
The “2023 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2028 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, discussing their products, strategic market position, background, and outlook.
Not seeing what you need?
In addition to our standard comprehensive reports, we also leverage our expert knowledge of the ophthalmic industry to design custom research that enhances strategy and operations for our clients. Our unique experience makes us a trusted partner in defining problems and executing solutions.
Common project types include custom data analysis, surveying and/or interviewing of ophthalmologists, focus groups, territory analyses, and other primary research initiatives -- but each project is custom designed to meet each specific clients' needs.
Please contact us for an individualized project consultation.
Want to Purchase the Full Report?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.